ClinicalTrials.gg
CompletedNCT06243198Updated Sep 12, 2025Results posted

A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

A Phase 1 interventional study of Lebrikizumab and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to determine the tolerability and side effects related to lebrikizumab comparing with placebo given as a single dose administered under the skin to healthy Chinese participants. The study will also assess how fast lebrikizumab gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either Lebrikizumab or placebo.

For each participant, the total duration of the study will be approximately up to 21 weeks, including screening period.

02

Conditions studied

  • Healthy

Keywords

  • Pharmacokinetics
  • Safety
  • Lebrikizumab
  • Chinese
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be overtly healthy, as determined by medical evaluation.
  • Have normal blood pressure, pulse rate, (ECG), blood and urine laboratory test results that are acceptable for the study.
  • Participants must be native Chinese and born in China, where the participant's biological parents and all 4 of the participant's biological grandparents are of Chinese origin.
  • Have a (BMI) within the range of 18.0 to 28.0 kilograms per square meter (kg/m²).
  • Have venous access sufficient to allow for blood sampling.

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to Lebrikizumab, related compounds, or any components of the formulation.
  • Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the medicinal product; or of interfering with the interpretation of data.
  • Have a history or presence of psychiatric disorders.
  • Have a history or presence of multiple or severe drug allergies.
  • Have significant allergies to monoclonal antibodies.
  • Show evidence of active or latent TB, infection , and C.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    250 mg Lebrikizumab

    Participants received single dose of 250 milligram (mg) lebrikizumab administered as subcutaneous (SC) injection on day 1.

    Drug: Lebrikizumab

  • Experimental
    500 mg Lebrikizumab

    Participants received single dose of 500 mg lebrikizumab administered as SC injection on day 1.

    Drug: Lebrikizumab

  • Placebo comparator
    Placebo

    Participants received single dose of placebo administered as SC injection on day 1.

    Drug: Placebo

Interventions

  • Administered subcutaneously (SC)

    Also known as: LY3650150

  • DrugPlacebo

    Administered subcutaneously (SC)

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)

    A TEAE is defined as an AE that starts during or after dosing, or starts prior to dosing and increases in severity after dosing. A SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; is an important medical event that may require medical or surgical intervention to prevent any of the above outcomes. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.

    Time frame: Baseline up to 120 days

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lebrikizumab

    PK: Cmax of Lebrikizumab is reported.

    Time frame: Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Lebrikizumab

    PK: AUC0-∞ of Lebrikizumab is reported.

    Time frame: Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab

    PK: AUC0-tlast of Lebrikizumab is reported.

    Time frame: Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose

07

Results

Posted Sep 12, 2025

Participant flow

Participant flow — Overall Study
Milestone250 mg Lebrikizumab500 mg LebrikizumabPlacebo
Started10104
Received at least one dose of study drug10104
Completed10104
Not completed000

Outcome measures

PrimaryNumber of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)

A TEAE is defined as an AE that starts during or after dosing, or starts prior to dosing and increases in severity after dosing. A SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria listed: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; is an important medical event that may require medical or surgical intervention to prevent any of the above outcomes. A summary of TEAEs, SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events section of this record.

Time frame:
Baseline up to 120 days
Reported as:
Number · participants
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs)
participants250 mg Lebrikizumab500 mg LebrikizumabPlacebo
TEAEs10103
SAEs000
SecondaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lebrikizumab

PK: Cmax of Lebrikizumab is reported.

Time frame:
Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose
Reported as:
Geometric mean · microgram per millilitre (µg/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lebrikizumab
microgram per millilitre (µg/mL)250 mg Lebrikizumab500 mg Lebrikizumab
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lebrikizumab26.8 ± 41.971.2 ± 22.1
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Lebrikizumab

PK: AUC0-∞ of Lebrikizumab is reported.

Time frame:
Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose
Reported as:
Geometric mean · microgram*day per milliliter (μg*day/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Lebrikizumab
microgram*day per milliliter (μg*day/mL)250 mg Lebrikizumab500 mg Lebrikizumab
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Lebrikizumab1130 ± 42.22940 ± 11.2
SecondaryPK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab

PK: AUC0-tlast of Lebrikizumab is reported.

Time frame:
Day 1: Predose and Days 2, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 120 post dose
Reported as:
Geometric mean · μg*day/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab
μg*day/mL250 mg Lebrikizumab500 mg Lebrikizumab
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab1080 ± 40.82800 ± 11.7

Adverse events

Collected over Baseline Up to 120 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
250 mg Lebrikizumab0/10 (0%)0/10 (0%)10/10 (100%)
500 mg Lebrikizumab0/10 (0%)0/10 (0%)10/10 (100%)
Placebo0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Showing 10 of 31
Most frequent other events
Event250 mg Lebrikizumab500 mg LebrikizumabPlacebo
Upper respiratory tract infectionInfections and infestations4/102/100/4
Mouth ulcerationGastrointestinal disorders3/101/101/4
Bilirubin conjugated increasedInvestigations1/103/100/4
Blood creatine phosphokinase increasedInvestigations1/103/101/4
Neutrophil count increasedInvestigations1/103/100/4
Noninfective gingivitisGastrointestinal disorders0/100/101/4
Blood triglycerides increasedInvestigations2/100/101/4
Urinary occult blood positiveInvestigations0/100/101/4
Weight increasedInvestigations0/101/101/4
PresyncopeNervous system disorders0/100/101/4

Baseline characteristics

All enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)250 mg Lebrikizumab500 mg LebrikizumabPlaceboTotal
Mean33.1 ± 8.0829.1 ± 5.9529.0 ± 6.2230.8 ± 6.97
Sex: Female, Male
Sex: Female, Male(Participants)250 mg Lebrikizumab500 mg LebrikizumabPlaceboTotal
Female2327
Male87217
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)250 mg Lebrikizumab500 mg LebrikizumabPlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino1010424
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)250 mg Lebrikizumab500 mg LebrikizumabPlaceboTotal
American Indian or Alaska Native0000
Asian1010424
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)250 mg Lebrikizumab500 mg LebrikizumabPlaceboTotal
China1010424
08

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing Municipality, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Sep 2024, 5 months.

Results were first posted in Sep 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2024
First posted
Feb 6, 2024
StartActual
Mar 28, 2024
Primary completionActual
Sep 3, 2024
CompletionActual
Sep 3, 2024
Results first posted
Sep 12, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06243198
Responsible party
Sponsor
First posted
Feb 6, 2024
Start date
Mar 28, 2024
Primary completion
Sep 3, 2024
Completion
Sep 3, 2024
Results posted
Sep 12, 2025
Last update
Sep 12, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion